Compare Five9 Inc (FIVN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs IDEXX Laboratories, Inc. — how do they compare? Five9 Inc trades at $25.06 (market cap $1.90B), while IDEXX Laboratories, Inc. trades at $573.19 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 23.1× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| FIVN | IDXX | |
|---|---|---|
Market Cap | $1.90B | $43.94B |
Sector | Technology | Health |
52-Week High | $29.16 | $766.68 |
52-Week Low | $13.61 | $514.61 |
Enterprise Value | $1.98B | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.05, down 2.07% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals, with revenue growing from $779M in 2022 to $1.15B in 2025 and turning profitable with net income of $39.42M. Recent news highlights AI product launches and workplace awards, while legal scrutiny on insider conduct persists.
The stock presents a positive outlook with strong analyst support (61% buy ratings) and a consensus price target of $27.00, offering ~8% upside. Key risks include negative net cash flow, high debt levels, and ongoing legal investigations into insider fiduciary duties that could pressure sentiment.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
